Emergent BioSolutions Income Statement (2010-2026) | EBS

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	377.40M	286.30M	732.90M	304.80M	242.60M	239.90M	330.20M	164.30M	337.90M	270.50M	276.60M	300.40M	50.00M	293.80M	194.70M	222.20M	140.90M	231.10M	148.70M	156.10M
Cost of Revenue (Quarter)	81.20M	1.10M	145.00M	0.90M	78.80M	85.20M	167.30M	152.90M	190.60M	176.80M	185.10M	144.60M	50.00M	122.60M	118.00M	88.50M	66.90M	85.90M	84.90M	72.00M
Gross Profit (Quarter)	296.20M	285.20M	587.90M	303.90M	163.80M	154.70M	162.90M	11.40M	147.30M	93.70M	91.50M	155.80M		171.20M	76.70M	133.70M	74.00M	145.20M	63.80M	84.10M
Operating items
Amortization - Intangibles (Quarter)	15.10M	14.50M	14.00M	14.00M	14.00M	14.00M	17.90M	17.00M	16.10M	16.30M	16.20M	16.20M	16.30M	16.30M	16.30M	16.30M	16.20M	16.30M	16.30M	16.50M
Research & Development (Quarter)	48.90M	49.60M	38.20M	46.40M	49.80M	42.20M	47.00M	40.70M	26.00M	15.30M	29.40M	15.10M	32.70M	13.80M	9.10M	15.10M	12.50M	13.50M	12.10M	10.50M
Selling, General & Administrative (Quarter)	91.20M	82.10M	94.50M	84.80M	81.10M	81.80M	93.40M	101.30M	91.40M	86.00M	89.70M	84.70M	85.90M	76.60M	60.80M	52.40M	43.70M	38.90M	51.10M	46.60M
Other Operating Expenses (Quarter)	242.90M	232.00M	305.20M	169.90M				169.90M	74.90M	-0.70M			-40.00M	64.30M		-12.20M
Operating Expenses (Quarter)	383.00M	363.70M	437.90M	301.10M	314.70M	285.20M	385.50M	311.90M	630.80M	512.60M	320.40M	260.60M	458.20M	229.30M	204.20M	172.30M	139.30M	154.60M	176.60M	145.60M
Operating Income (Quarter)	7.10M	-44.70M	286.80M	6.90M	-76.30M	-45.30M	-55.30M	-147.60M	-292.90M	-242.10M	-43.80M	39.80M	-203.50M	64.50M	-9.50M	49.90M	1.60M	76.50M	-27.90M	10.50M
EBIT (Quarter)	7.10M	-44.70M	286.80M	6.90M	-76.30M	-45.30M	-55.30M	-147.60M	-292.90M	-242.10M	-43.80M	39.80M	-203.50M	64.50M	-9.50M	49.90M	1.60M	76.50M	-27.90M	10.50M
Non-operating items
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)	1.30M	-2.40M	-0.90M	-2.00M	-3.00M	-13.40M	6.70M	4.90M	-3.60M	-3.40M	4.60M	-3.40M	-2.70M	21.90M	-15.20M	69.70M	-3.70M	-3.70M	-13.80M	13.90M
Non Operating Income (Quarter)	1.30M	-2.40M	-0.90M	-2.00M	-3.00M	-21.90M	-30.60M	4.90M	-3.60M	-23.80M	8.50M	-27.70M	-66.30M	21.90M	-18.10M	69.70M	-18.40M	-3.70M	-22.80M	2.90M
Net income details
EBT (Quarter)	7.20M	-45.50M	256.30M	-3.80M	-82.80M	-67.20M	-61.40M	-160.60M	-250.20M	-265.90M	-54.50M	12.10M	-269.80M	142.40M	-27.60M	92.70M	-16.80M	57.60M	-50.70M	13.40M
Tax Provisions (Quarter)	2.60M	-12.80M	78.40M	-0.10M	-26.40M	19.90M	5.60M	25.60M	11.20M	-2.50M	-5.00M	3.10M	13.30M	27.60M	3.70M	24.70M	-4.80M	6.40M	3.90M	6.60M
Profit After Tax (Quarter)	-0.50M	-40.40M	193.10M	-4.60M	-52.90M	-87.10M	-67.00M	-186.20M	-261.40M	-263.40M	-49.50M	9.00M	-283.10M	114.80M	-31.30M	68.00M	-12.00M	51.20M	-54.60M	6.80M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)	4.60M	-32.70M	177.90M	-3.70M	-56.40M	-87.10M	-67.00M	-186.20M	-261.40M	-263.40M	-49.50M	9.00M	-283.10M	114.80M	-31.30M	68.00M	-12.00M	51.20M	-54.60M	6.80M
Consolidated Net Income (Quarter)	4.60M	-32.70M	177.90M	-3.70M	-56.40M	-87.10M	-67.00M	-186.20M	-261.40M	-263.40M	-49.50M	9.00M	-283.10M	114.80M	-31.30M	68.00M	-12.00M	51.20M	-54.60M	6.80M
Income towards Parent Company (Quarter)	4.60M	-32.70M	177.90M	-3.70M	-56.40M	-87.10M	-67.00M	-186.20M	-261.40M	-263.40M	-49.50M	9.00M	-283.10M	114.80M	-31.30M	68.00M	-12.00M	51.20M	-54.60M	6.80M
Net Income towards Common Stockholders (Quarter)	4.60M	-32.70M	177.90M	-3.70M	-56.40M	-87.10M	-67.00M	-186.20M	-261.40M	-263.40M	-49.50M	9.00M	-283.10M	114.80M	-31.30M	68.00M	-12.00M	51.20M	-54.60M	6.80M
Additional items
EPS (Basic) (Quarter)	-0.01	-0.75	3.62	-0.09	-1.06	-1.75	-1.34	-3.71	-5.16	-5.08	-0.88	0.17	-5.38	2.16	-0.57	1.25	-0.22	0.96	-1.01	0.13
EPS (Weighted Average and Diluted) (Quarter)	-0.01	-0.75	3.60	-0.09	-1.06	-1.75	-1.34	-3.71	-5.16	-5.08	-0.88	0.17	-5.38	2.06	-0.57	1.19	-0.22	0.91	-0.96	0.07
Shares Outstanding (Weighted Average) (Quarter)	53.60M	53.60M	53.50M	50.70M	50.00M	50.20M	50.10M	50.20M	50.70M	51.80M	51.20M	52.20M	52.40M	53.10M	53.00M	54.40M	54.30M	53.90M	53.50M	51.90M
Shares Outstanding (Diluted Average) (Quarter)	54.00M	53.70M	54.10M	50.70M	50.30M	50.20M	50.10M	50.20M	50.50M	51.80M	51.20M	52.20M	52.40M	55.60M	53.00M	57.30M	56.70M	56.50M	56.70M	56.50M
EBITDA (Quarter)	7.10M	-44.70M	286.80M	6.90M	-76.30M	-45.30M	-55.30M	-147.60M	-292.90M	-242.10M	-43.80M	39.80M	-203.50M	64.50M	-9.50M	49.90M	1.60M	76.50M	-27.90M	10.50M
Interest Expenses (Quarter)	8.60M	8.40M	9.00M	8.20M	7.80M	8.50M	12.80M	17.90M	28.60M	19.70M	21.70M	24.30M	23.60M	8.30M	14.80M	14.70M	14.70M	15.20M	14.70M	11.00M
Tax Rate (Quarter)	36.11%	28.13%	30.59%	2.63%	31.88%	-29.61%	-9.12%	-15.94%	-4.48%	0.94%	9.17%	25.62%	-4.93%	19.38%	-13.41%	26.65%	28.57%	11.11%	-7.69%	49.25%

Research Tools

Emergent BioSolutions Income Statement (2010-2026) | EBS

Create an account

Sign In

Reset Password